Literature DB >> 6206903

Study of the expression of a glycoprotein of retroviral origin in the plasma of patients with hematologic disorders and in the plasma of normal individuals.

P C Jacquemin, P Strijckmans, L Thiry.   

Abstract

A 74,000 molecular weight glycoprotein was purified from the plasma of a patient with chronic myelogenous leukemia in blast crisis. Monoclonal antibodies were produced in the mouse and used to characterize this protein. It was shown to contain p15E antigenic determinants and portions of a reverse transcriptase. The level of this protein was found to be elevated in leukemic patients with high white blood cell counts and also in some patients with other hematopoietic disorders as compared to the level measured in normal individuals. The level of the protein was strongly reduced in acute leukemia patients after intense chemotherapy treatment. We tentatively conclude that this protein is of endogenous retroviral origin and perhaps regulates hematopoietic tissues.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6206903

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  Chronic fatigue syndrome is not associated with expression of endogenous retroviral p15E.

Authors:  I H Gelman; E R Unger; A C Mawle; R Nisenbaum; W C Reeves
Journal:  Mol Diagn       Date:  2000-06

2.  Sequence variation of human endogenous retrovirus ERV9-related elements in an env region corresponding to an immunosuppressive peptide: transcription in normal and neoplastic cells.

Authors:  M Lindeskog; P Medstrand; J Blomberg
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

3.  Inhibition of rat yolk sac tumour growth in vivo by a monoclonal antibody to the retroviral molecule P15E.

Authors:  M Lindvall; H O Sjögren
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 4.  Human endogenous retroviruses: nature, occurrence, and clinical implications in human disease.

Authors:  H B Urnovitz; W H Murphy
Journal:  Clin Microbiol Rev       Date:  1996-01       Impact factor: 26.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.